尿酸水平和心血管和脑血管疾病:孟德尔的随机化研究
Xiaowen Hou1, Kaiwen Cen1, Yunfeng Zhu2
1School of Public Health, Shenyang Medical College, Shenyang, China.
Cerebrovascular diseases (Basel, Switzerland)
|October 6, 2024
概括
尿酸 (UA) 水平升高因果性地增加了中风,冠状动脉疾病 (CAD) 和心房动的风险. 这项门德尔的随机化研究证实了UA的存在.
科学领域:
- 心血管流行病学心血管流行病学
- 遗传流行病学遗传流行病学
- 代谢性疾病研究研究
背景情况:
- 尿酸 (UA) 水平与心血管和脑血管疾病 (CCVD) 之间的关联仍在争论中.
- 之前的观察性研究对这种关系产生了相互矛盾的结果.
研究的目的:
- 调查基因预测尿酸水平与CCVD风险之间的潜在因果关系.
- 利用门德尔的随机化 (MR) 来推断因果关系,克服观察性研究的局限性.
主要方法:
- 采用了一个双样本的门德尔随机化研究设计.
- 从一个大型基因组广泛关联研究 (GWAS) 数据集 (n=110,347) 中确定了与UA水平密切相关的遗传变异.
- 逆变量加权 (IVW) 方法是主要分析,MR-Egger和加权中位数作为对中风,冠状动脉疾病 (CAD) 和心房动和动的灵敏度分析.
主要成果:
- 在中风 (OR: 1.002,p=0.036),CAD (OR: 1.118,p=0.001) 和心房动和动 (OR: 1.141,p=0.007) 中观察到UA水平的显著因果作用.
- 使用MR-Egger和加权中位数的灵敏度分析证实了主要发现,表明了强大的关联.
- 没有检测到显著的异质性或质性,支持MR分析的有效性.
结论:
- 尿酸水平似乎对中风的发展有直接的因果影响.
- 尿酸水平升高与冠状动脉疾病风险增加有关.
- 高尿酸水平与心房动和动的可能性增加之间存在因果关系.
相关概念视频
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...